ClinicalTrials.gg
RecruitingNCT02530073FETOUpdated Jun 18, 2026

Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

An interventional study of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Congenital Diaphragmatic Hernias, sponsored by Connecticut Children's Medical Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Connecticut Children's Medical Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2015; still recruiting 11 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-14

Among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States — 24 open to participants now, 28 under way, 2 of them phase 3. Hernias, Diaphragmatic, Congenital · United States.

Planned enrollment
23rd of 36
15 · median 21
Started
2015
with 3 others
No phase
28 of 45
18 open now
Primary completion
2028-08
later than 11 of 27 live
Registered
10th of 45
by date

Among the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, this one is the 23rd largest by planned enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2015, is one of 28 with no phase, reaches primary completion later than 11 of the 27 other live ones, and was the 10th registered.

Hernias, Diaphragmatic, Congenital

86 studies on the registry are indexed under Hernias, Diaphragmatic, Congenital; 39 are open to participants now.

Browse Hernias, Diaphragmatic, Congenital studies →

Open to participants now

24 of the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 32 Hernias, Diaphragmatic, Congenital studies recruiting now, 16 (50%) set no upper age limit and 16 (50%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, or all of them as a file.
02

Study summary

The rationale for fetal therapy in severe congenital diaphragmatic hernia (CDH) is to restore adequate lung growth for neonatal survival.

Read the detailed description

Prenatal tracheal occlusion (TO) obstructs the normal egress of lung fluid during pulmonary development leading to increased lung tissue stretch, increased cell proliferation, and accelerated lung growth. European colleagues have developed foregut endoscopy and techniques to position and remove endoluminal tracheal balloons in utero. Recently, the Belgium group published summary results of FETO showing an improved survival in 175 patients with isolated left CDH from 24% to 49%.

The goal of this pilot study is to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH Observed/expected lung-to-head ratio \< 25%(O/E LHR \< 25%).

03

Conditions studied

  • Congenital Diaphragmatic Hernias

Keywords

  • congenital diaphragmatic hernia
  • FETO
  • tracheal occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women age 18 years and older, who are able to consent
  • Singleton pregnancy

Fetal

  • Normal Karyotype
  • Fetal Diagnosis of Isolated Left CDH with liver up
  • Gestation at enrollment prior to 29 wks plus 6 days
  • SEVERE pulmonary hypoplasia with Ultra Sound O/E LHR \< 25%

Exclusion criteria

Exclusion Criteria:

  • Pregnant women \<18 years of age.
  • Maternal to fetoscopic surgery or severe maternal medical condition in pregnancy
  • Technical limitations precluding fetoscopic surgery
  • Rubber latex allergy
  • Preterm labor, cervix shortened (\<15 mm at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor, placenta previa
  • Psychosocial ineligibility, precluding consent
  • Diaphragmatic hernia: right-sided or bilateral, major associated anomalies, isolated left-sided with the O/E LHR ≥ 25%
  • Inability to remain at FETO site during time period of tracheal occlusion, delivery and postnatal care
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Fetoscopic Endoluminal Tracheal Occlusion (FETO)

    An un-blinded non-randomized single arm pilot study of FETO in fetuses with congenital diaphragmatic hernia (CDH)

    Device: Fetoscopic Endoluminal Tracheal Occlusion (FETO)

Interventions

  • DeviceFetoscopic Endoluminal Tracheal Occlusion (FETO)

    This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH and observed/expected length head ratio \<25% (O/E LHR).

    Also known as: BALT GOLDBAL2 Tracheal Balloon Catheter system

06

What researchers measure

Primary outcomes

  1. Percent of neonatal survivors at time of discharge

    Feasibility, safety, and survival rates of the FETO procedure

    Time frame: Discharge from the hospital, an expected average of 12 weeks.

Secondary outcomes

  1. Prenatal increase in lung volume

    Lung volume after FETO procedure

    Time frame: 2 weeks (prenatally)

  2. Number of days of Postnatal mechanical ventilator support

    mechanical ventilator support will be monitored and recorded in days of use

    Time frame: First 28 days of postnatal life

  3. Changes in RNA content of tracheal and amniotic fluid

    Describe how tracheal occlusion affects the RNA content of amniotic and tracheal fluid in CDH fetuses, and to correlate this transcriptomic profile to the degree of lung hypoplasia and fetal and neonatal clinical outcomes.

    Time frame: At time of balloon placement and removal

  4. Characterization of extracellular vesicles (EVs) and miRNAs in tracheal and amniotic fluid

    To describe how extracellular vesicles (EVs) are derived from the amniotic and tracheal fluid of CDH patients before and after tracheal occlusion, and to determine whether the identified miRNAs of interest are intra- or extra-vesicular.

    Time frame: At time of balloon placement and removal

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2015 (actual). Primary completion is estimated for Aug 2028, 155 months after the start.

Of 40 interventional studies with no phase under Hernias, Diaphragmatic, Congenital, half reached primary completion within 108 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 133. This study's planned 155 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2015
First posted
Aug 20, 2015
StartActual
Sep 2015
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2030
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02530073
Lead sponsor
Connecticut Children's Medical Center
Responsible party
Timothy Crombleholme (Director of Fetal Care Center, Connecticut Children's Medical Center) — Principal investigator
First posted
Aug 20, 2015
Start date
Sep 2015
Primary completion
Aug 2028 (estimated)
Completion
Aug 2030 (estimated)
Last update
Jun 18, 2026

Study contacts

Katie E Boyle, MPH
Contact
Kboyle01@connecticutchildrens.org
860-837-6547
Timothy Crombleholme, MD
principal investigator · Connecticut Children's Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion